Browsing Tag
PSMAfore
1 post
Novartis wins FDA nod for Pluvicto in hormone-sensitive prostate cancer, nearly doubling its addressable pool
FDA's mHSPC label nod nearly doubles Pluvicto's addressable pool. Novartis' five RLT plants and payer coverage now decide how fast $651M Q2 sales scale.